171 results on '"Frederiksen, Kristian S."'
Search Results
2. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
- Author
-
Jansen, Willemijn J, Ossenkoppele, Rik, Tijms, Betty M, Fagan, Anne M, Hansson, Oskar, Klunk, William E, van der Flier, Wiesje M, Villemagne, Victor L, Frisoni, Giovanni B, Fleisher, Adam S, Lleó, Alberto, Mintun, Mark A, Wallin, Anders, Engelborghs, Sebastiaan, Na, Duk L, Chételat, Gäel, Molinuevo, José Luis, Landau, Susan M, Mattsson, Niklas, Kornhuber, Johannes, Sabri, Osama, Rowe, Christopher C, Parnetti, Lucilla, Popp, Julius, Fladby, Tormod, Jagust, William J, Aalten, Pauline, Lee, Dong Young, Vandenberghe, Rik, de Oliveira, Catarina Resende, Kapaki, Elisabeth, Froelich, Lutz, Ivanoiu, Adrian, Gabryelewicz, Tomasz, Verbeek, Marcel M, Sanchez-Juan, Páscual, Hildebrandt, Helmut, Camus, Vincent, Zboch, Marzena, Brooks, David J, Drzezga, Alexander, Rinne, Juha O, Newberg, Andrew, de Mendonça, Alexandre, Sarazin, Marie, Rabinovici, Gil D, Madsen, Karine, Kramberger, Milica G, Nordberg, Agneta, Mok, Vincent, Mroczko, Barbara, Wolk, David A, Meyer, Philipp T, Tsolaki, Magda, Scheltens, Philip, Verhey, Frans RJ, Visser, Pieter Jelle, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Almdahl, Ina S, Arnold, Steven E, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart NM, Blennow, Kaj, van Buchem, Mark A, Cavedo, Enrica, Chen, Kewei, Chipi, Elena, Cohen, Ann D, Förster, Stefan, Fortea, Juan, Frederiksen, Kristian S, Freund-Levi, Yvonne, Gkatzima, Olymbia, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Johannsen, Peter, Klimkowicz-Mrowiec, Aleksandra, Köhler, Sebastian, Koglin, Norman, van Laere, Koen, de Leon, Mony, Lisetti, Viviana, Maier, Wolfgang, Marcusson, Jan, Meulenbroek, Olga, Møllergård, Hanne M, Morris, John C, Nordlund, Arto, Novak, Gerald P, Paraskevas, George P, Perera, Gayan, Peters, Oliver, and Ramakers, Inez HGB
- Subjects
Health Services and Systems ,Health Sciences ,Acquired Cognitive Impairment ,Alzheimer's Disease Related Dementias (ADRD) ,Neurosciences ,Aging ,Dementia ,Brain Disorders ,Behavioral and Social Science ,Neurodegenerative ,Alzheimer's Disease ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Clinical Research ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Mental health ,Aged ,Alzheimer Disease ,Amyloid beta-Peptides ,Brain ,Cognition Disorders ,Cognitive Dysfunction ,Cross-Sectional Studies ,Female ,Humans ,Male ,Memory ,Episodic ,Mental Status and Dementia Tests ,Middle Aged ,Positron-Emission Tomography ,Reference Values ,Amyloid Biomarker Study Group ,Other Medical and Health Sciences ,Psychology ,Cognitive Sciences ,Clinical sciences ,Clinical and health psychology - Abstract
ImportanceCerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.ObjectiveTo investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.Design, setting, and participantsThis cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017.Main outcomes and measuresGlobal cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype.ResultsAmong 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P
- Published
- 2018
3. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
- Author
-
Frisoni, Giovanni B., Festari, Cristina, Massa, Federico, Cotta Ramusino, Matteo, Orini, Stefania, Aarsland, Dag, Agosta, Federica, Babiloni, Claudio, Borroni, Barbara, Cappa, Stefano F., Frederiksen, Kristian S., Froelich, Lutz, Garibotto, Valentina, Haliassos, Alexander, Jessen, Frank, Kamondi, Anita, Kessels, Roy PC, Morbelli, Silvia D., O'Brien, John T., Otto, Markus, Perret-Liaudet, Armand, Pizzini, Francesca B., Vandenbulcke, Mathieu, Vanninen, Ritva, Verhey, Frans, Vernooij, Meike W., Yousry, Tarek, Boada Rovira, Mercè, Dubois, Bruno, Georges, Jean, Hansson, Oskar, Ritchie, Craig W., Scheltens, Philip, van der Flier, Wiesje M., Nobili, Flavio, Frisoni, Giovanni B., Festari, Cristina, Massa, Federico, Cotta Ramusino, Matteo, Orini, Stefania, Aarsland, Dag, Agosta, Federica, Babiloni, Claudio, Borroni, Barbara, Cappa, Stefano F., Frederiksen, Kristian S., Froelich, Lutz, Garibotto, Valentina, Haliassos, Alexander, Jessen, Frank, Kamondi, Anita, Kessels, Roy PC, Morbelli, Silvia D., O'Brien, John T., Otto, Markus, Perret-Liaudet, Armand, Pizzini, Francesca B., Vandenbulcke, Mathieu, Vanninen, Ritva, Verhey, Frans, Vernooij, Meike W., Yousry, Tarek, Boada Rovira, Mercè, Dubois, Bruno, Georges, Jean, Hansson, Oskar, Ritchie, Craig W., Scheltens, Philip, van der Flier, Wiesje M., and Nobili, Flavio
- Abstract
The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.
- Published
- 2024
4. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
- Author
-
Jansen, Willemijn J, Ossenkoppele, Rik, Knol, Dirk L, Tijms, Betty M, Scheltens, Philip, Verhey, Frans RJ, Visser, Pieter Jelle, Aalten, Pauline, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Almdahl, Ina S, Arnold, Steven E, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart NM, Bibeau, Kristen, Blennow, Kaj, Brooks, David J, van Buchem, Mark A, Camus, Vincent, Cavedo, Enrica, Chen, Kewei, Chetelat, Gael, Cohen, Ann D, Drzezga, Alexander, Engelborghs, Sebastiaan, Fagan, Anne M, Fladby, Tormod, Fleisher, Adam S, van der Flier, Wiesje M, Ford, Lisa, Förster, Stefan, Fortea, Juan, Foskett, Nadia, Frederiksen, Kristian S, Freund-Levi, Yvonne, Frisoni, Giovanni B, Froelich, Lutz, Gabryelewicz, Tomasz, Gill, Kiran Dip, Gkatzima, Olymbia, Gómez-Tortosa, Estrella, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Hildebrandt, Helmut, Ishihara, Lianna, Ivanoiu, Adrian, Jagust, William J, Johannsen, Peter, Kandimalla, Ramesh, Kapaki, Elisabeth, Klimkowicz-Mrowiec, Aleksandra, Klunk, William E, Köhler, Sebastian, Koglin, Norman, Kornhuber, Johannes, Kramberger, Milica G, Van Laere, Koen, Landau, Susan M, Lee, Dong Young, de Leon, Mony, Lisetti, Viviana, Lleó, Alberto, Madsen, Karine, Maier, Wolfgang, Marcusson, Jan, Mattsson, Niklas, de Mendonça, Alexandre, Meulenbroek, Olga, Meyer, Philipp T, Mintun, Mark A, Mok, Vincent, Molinuevo, José Luis, Møllergård, Hanne M, Morris, John C, Mroczko, Barbara, Van der Mussele, Stefan, Na, Duk L, Newberg, Andrew, Nordberg, Agneta, Nordlund, Arto, Novak, Gerald P, Paraskevas, George P, Parnetti, Lucilla, Perera, Gayan, Peters, Oliver, Popp, Julius, Prabhakar, Sudesh, Rabinovici, Gil D, Ramakers, Inez HGB, Rami, Lorena, de Oliveira, Catarina Resende, Rinne, Juha O, Rodrigue, Karen M, and Rodríguez-Rodríguez, Eloy
- Subjects
Health Services and Systems ,Health Sciences ,Clinical Research ,Alzheimer's Disease ,Vascular Cognitive Impairment/Dementia ,Acquired Cognitive Impairment ,Neurosciences ,Alzheimer's Disease Related Dementias (ADRD) ,Brain Disorders ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Cerebrovascular ,Neurodegenerative ,Prevention ,Dementia ,Aging ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Adult ,Age Factors ,Aged ,Aged ,80 and over ,Amyloid beta-Peptides ,Apolipoprotein E4 ,Biomarkers ,Brain ,Cerebrospinal Fluid ,Cognitive Dysfunction ,Female ,Genotype ,Humans ,Male ,Middle Aged ,Positron-Emission Tomography ,Prevalence ,Risk Factors ,Amyloid Biomarker Study Group ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceCerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.ObjectiveTo use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).Data sourcesRelevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators.Study selectionStudies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity.Data extraction and synthesisIndividual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.Main outcomes and measuresPrevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.ResultsThe prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality.Conclusions and relevanceAmong persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.
- Published
- 2015
5. Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
- Author
-
Ossenkoppele, Rik, Jansen, Willemijn J, Rabinovici, Gil D, Knol, Dirk L, van der Flier, Wiesje M, van Berckel, Bart NM, Scheltens, Philip, Visser, Pieter Jelle, Verfaillie, Sander CJ, Zwan, Marissa D, Adriaanse, Sofie M, Lammertsma, Adriaan A, Barkhof, Frederik, Jagust, William J, Miller, Bruce L, Rosen, Howard J, Landau, Susan M, Villemagne, Victor L, Rowe, Christopher C, Lee, Dong Y, Na, Duk L, Seo, Sang W, Sarazin, Marie, Roe, Catherine M, Sabri, Osama, Barthel, Henryk, Koglin, Norman, Hodges, John, Leyton, Cristian E, Vandenberghe, Rik, van Laere, Koen, Drzezga, Alexander, Forster, Stefan, Grimmer, Timo, Sánchez-Juan, Pascual, Carril, Jose M, Mok, Vincent, Camus, Vincent, Klunk, William E, Cohen, Ann D, Meyer, Philipp T, Hellwig, Sabine, Newberg, Andrew, Frederiksen, Kristian S, Fleisher, Adam S, Mintun, Mark A, Wolk, David A, Nordberg, Agneta, Rinne, Juha O, Chételat, Gaël, Lleo, Alberto, Blesa, Rafael, Fortea, Juan, Madsen, Karine, Rodrigue, Karen M, and Brooks, David J
- Subjects
Health Services and Systems ,Health Sciences ,Genetics ,Acquired Cognitive Impairment ,Clinical Research ,Neurodegenerative ,Alzheimer's Disease ,Brain Disorders ,Aging ,Biomedical Imaging ,Neurosciences ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Dementia ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Adult ,Age Factors ,Aged ,Aged ,80 and over ,Amyloid beta-Peptides ,Apolipoprotein E4 ,Brain ,Female ,Genotype ,Humans ,Male ,Middle Aged ,Positron-Emission Tomography ,Prevalence ,Risk Factors ,Amyloid PET Study Group ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceAmyloid-β positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.ObjectiveTo use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.Data sourcesThe MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies.Study selectionCase reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data.Data extraction and synthesisData were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy).Main outcomes and measuresEstimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) ε4 status, using the generalized estimating equations method.ResultsThe likelihood of amyloid positivity was associated with age and APOE ε4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE ε4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n = 377) and to a lesser degree in APOE ε4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n = 593; P
- Published
- 2015
6. The EADC‐ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity
- Author
-
Frisoni, Giovanni B, Jack, Clifford R, Bocchetta, Martina, Bauer, Corinna, Frederiksen, Kristian S, Liu, Yawu, Preboske, Gregory, Swihart, Tim, Blair, Melanie, Cavedo, Enrica, Grothe, Michel J, Lanfredi, Mariangela, Martinez, Oliver, Nishikawa, Masami, Portegies, Marileen, Stoub, Travis, Ward, Chadwich, Apostolova, Liana G, Ganzola, Rossana, Wolf, Dominik, Barkhof, Frederik, Bartzokis, George, DeCarli, Charles, Csernansky, John G, deToledo‐Morrell, Leyla, Geerlings, Mirjam I, Kaye, Jeffrey, Killiany, Ronald J, Lehéricy, Stephane, Matsuda, Hiroshi, O'Brien, John, Silbert, Lisa C, Scheltens, Philip, Soininen, Hilkka, Teipel, Stefan, Waldemar, Gunhild, Fellgiebel, Andreas, Barnes, Josephine, Firbank, Michael, Gerritsen, Lotte, Henneman, Wouter, Malykhin, Nikolai, Pruessner, Jens C, Wang, Lei, Watson, Craig, Wolf, Henrike, deLeon, Mony, Pantel, Johannes, Ferrari, Clarissa, Bosco, Paolo, Pasqualetti, Patrizio, Duchesne, Simon, Duvernoy, Henri, Boccardi, Marina, Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging, Albert, Marilyn S, Bennet, David, Camicioli, Richard, Collins, D Louis, Dubois, Bruno, Hampel, Harald, denHeijer, Tom, Hock, Christofer, Jagust, William, Launer, Leonore, Maller, Jerome J, Mueller, Susan, Sachdev, Perminder, Simmons, Andy, Thompson, Paul M, Visser, Peter‐Jelle, Wahlund, Lars‐Olof, Weiner, Michael W, and Winblad, Bengt
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Brain Disorders ,Biomedical Imaging ,Clinical Research ,Aged ,Alzheimer Disease ,Atrophy ,Female ,Functional Laterality ,Hippocampus ,Humans ,Image Processing ,Computer-Assisted ,Imaging ,Three-Dimensional ,Internet ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Neuroimaging ,Organ Size ,Reproducibility of Results ,Hippocampal volumetry ,Magnetic resonance ,Alzheimer's disease ,Biomarkers ,Diagnostic criteria ,Enrichment ,Clinical trials ,Validation ,Harmonized protocol ,Standard operating procedures ,Manual segmentation ,EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging Initiative ,Geriatrics ,Clinical sciences ,Biological psychology - Abstract
BackgroundAn international Delphi panel has defined a harmonized protocol (HarP) for the manual segmentation of the hippocampus on MR. The aim of this study is to study the concurrent validity of the HarP toward local protocols, and its major sources of variance.MethodsFourteen tracers segmented 10 Alzheimer's Disease Neuroimaging Initiative (ADNI) cases scanned at 1.5 T and 3T following local protocols, qualified for segmentation based on the HarP through a standard web-platform and resegmented following the HarP. The five most accurate tracers followed the HarP to segment 15 ADNI cases acquired at three time points on both 1.5 T and 3T.ResultsThe agreement among tracers was relatively low with the local protocols (absolute left/right ICC 0.44/0.43) and much higher with the HarP (absolute left/right ICC 0.88/0.89). On the larger set of 15 cases, the HarP agreement within (left/right ICC range: 0.94/0.95 to 0.99/0.99) and among tracers (left/right ICC range: 0.89/0.90) was very high. The volume variance due to different tracers was 0.9% of the total, comparing favorably to variance due to scanner manufacturer (1.2), atrophy rates (3.5), hemispheric asymmetry (3.7), field strength (4.4), and significantly smaller than the variance due to atrophy (33.5%, P < .001), and physiological variability (49.2%, P < .001).ConclusionsThe HarP has high measurement stability compared with local segmentation protocols, and good reproducibility within and among human tracers. Hippocampi segmented with the HarP can be used as a reference for the qualification of human tracers and automated segmentation algorithms.
- Published
- 2015
7. Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease
- Author
-
Frederiksen, Kristian S., Madsen, Karine, Andersen, Birgitte B., Beyer, Nina, Garde, Ellen, Høgh, Peter, Waldemar, Gunhild, Hasselbalch, Steen G., and Law, Ian
- Published
- 2019
- Full Text
- View/download PDF
8. Detecting frontotemporal dementia syndromes using MRI biomarkers
- Author
-
Bruun, Marie, Koikkalainen, Juha, Rhodius-Meester, Hanneke F.M., Baroni, Marta, Gjerum, Le, van Gils, Mark, Soininen, Hilkka, Remes, Anne M., Hartikainen, Päivi, Waldemar, Gunhild, Mecocci, Patrizia, Barkhof, Frederik, Pijnenburg, Yolande, van der Flier, Wiesje M., Hasselbalch, Steen G., Lötjönen, Jyrki, and Frederiksen, Kristian S.
- Published
- 2019
- Full Text
- View/download PDF
9. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
- Author
-
Mattsson, Niklas, Groot, Colin, Jansen, Willemijn J., Landau, Susan M., Villemagne, Victor L., Engelborghs, Sebastiaan, Mintun, Mark M., Lleo, Alberto, Molinuevo, José Luis, Jagust, William J., Frisoni, Giovanni B., Ivanoiu, Adrian, Chételat, Gaël, Resende de Oliveira, Catarina, Rodrigue, Karen M., Kornhuber, Johannes, Wallin, Anders, Klimkowicz-Mrowiec, Aleksandra, Kandimalla, Ramesh, Popp, Julius, Aalten, Pauline P., Aarsland, Dag, Alcolea, Daniel, Almdahl, Ina S., Baldeiras, Inês, van Buchem, Mark A., Cavedo, Enrica, Chen, Kewei, Cohen, Ann D., Förster, Stefan, Fortea, Juan, Frederiksen, Kristian S., Freund-Levi, Yvonne, Gill, Kiran Dip, Gkatzima, Olymbia, Grimmer, Timo, Hampel, Harald, Herukka, Sanna-Kaisa, Johannsen, Peter, van Laere, Koen, de Leon, Mony J., Maier, Wolfgang, Marcusson, Jan, Meulenbroek, Olga, Møllergård, Hanne M., Morris, John C., Mroczko, Barbara, Nordlund, Arto, Prabhakar, Sudesh, Peters, Oliver, Rami, Lorena, Rodríguez-Rodríguez, Eloy, Roe, Catherine M., Rüther, Eckart, Santana, Isabel, Schröder, Johannes, Seo, Sang W., Soininen, Hilkka, Spiru, Luiza, Stomrud, Erik, Struyfs, Hanne, Teunissen, Charlotte E., Verhey, Frans R.J., Vos, Stephanie J.B., van Waalwijk van Doorn, Linda J.C., Waldemar, Gunhild, Wallin, Åsa K., Wiltfang, Jens, Vandenberghe, Rik, Brooks, David J., Fladby, Tormod, Rowe, Christopher C., Drzezga, Alexander, Verbeek, Marcel M., Sarazin, Marie, Wolk, David A., Fleisher, Adam S., Klunk, William E., Na, Duk L., Sánchez-Juan, Pascual, Lee, Dong Young, Nordberg, Agneta, Tsolaki, Magda, Camus, Vincent, Rinne, Juha O., Fagan, Anne M., Zetterberg, Henrik, Blennow, Kaj, Rabinovici, Gil D., Hansson, Oskar, van Berckel, Bart N.M., van der Flier, Wiesje M., Scheltens, Philip, Visser, Pieter Jelle, and Ossenkoppele, Rik
- Published
- 2018
- Full Text
- View/download PDF
10. Evaluating combinations of diagnostic tests to discriminate different dementia types
- Author
-
Bruun, Marie, Rhodius-Meester, Hanneke F.M., Koikkalainen, Juha, Baroni, Marta, Gjerum, Le, Lemstra, Afina W., Barkhof, Frederik, Remes, Anne M., Urhemaa, Timo, Tolonen, Antti, Rueckert, Daniel, van Gils, Mark, Frederiksen, Kristian S., Waldemar, Gunhild, Scheltens, Philip, Mecocci, Patrizia, Soininen, Hilkka, Lötjönen, Jyrki, Hasselbalch, Steen G., and van der Flier, Wiesje M.
- Published
- 2018
- Full Text
- View/download PDF
11. The effect of physical exercise on cerebral blood flow in Alzheimer's disease
- Author
-
van der Kleij, Lisa A., Petersen, Esben T., Siebner, Hartwig R., Hendrikse, Jeroen, Frederiksen, Kristian S., Sobol, Nanna A., Hasselbalch, Steen G., and Garde, Ellen
- Published
- 2018
- Full Text
- View/download PDF
12. Automatically computed rating scales from MRI for patients with cognitive disorders
- Author
-
Koikkalainen, Juha R., Rhodius-Meester, Hanneke F. M., Frederiksen, Kristian S., Bruun, Marie, Hasselbalch, Steen G., Baroni, Marta, Mecocci, Patrizia, Vanninen, Ritva, Remes, Anne, Soininen, Hilkka, van Gils, Mark, van der Flier, Wiesje M., Scheltens, Philip, Barkhof, Frederik, Erkinjuntti, Timo, Lötjönen, Jyrki M. P., and for the Alzheimer’s Disease Neuroimaging Initiative
- Published
- 2019
- Full Text
- View/download PDF
13. The role of physical and cognitive function in performance of activities of daily living in patients with mild-to-moderate Alzheimer’s disease – a cross-sectional study
- Author
-
Clemmensen, Frederikke K, Hoffmann, Kristine, Siersma, Volkert, Sobol, Nanna, Beyer, Nina, Andersen, Birgitte B, Vogel, Asmus, Lolk, Annette, Gottrup, Hanne, Høgh, Peter, Waldemar, Gunhild, Hasselbalch, Steen G, and Frederiksen, Kristian S
- Published
- 2020
- Full Text
- View/download PDF
14. European consensus for the diagnosis of MCI and mild dementia:Preparatory phase
- Author
-
Festari, Cristina, Massa, Federico, Cotta Ramusino, Matteo, Gandolfo, Federica, Nicolosi, Valentina, Orini, Stefania, Aarsland, Dag, Agosta, Federica, Babiloni, Claudio, Boada, Merce, Borroni, Barbara, Cappa, Stefano, Dubois, Bruno, Frederiksen, Kristian S., Froelich, Lutz, Garibotto, Valentina, Georges, Jean, Haliassos, Alexander, Hansson, Oskar, Jessen, Frank, Kamondi, Anita, Kessels, Roy P. C., Morbelli, Silvia, O'Brien, John T., Otto, Markus, Perret-Liaudet, Armand, Pizzini, Francesca B., Ritchie, Craig W., Scheltens, Philip, Vandenbulcke, Mathieu, Vanninen, Ritva, Verhey, Frans, Vernooij, Meike W., Yousry, Tarek, Van der Flier, Wiesje M., Nobili, Flavio, Frisoni, Giovanni B., Festari, Cristina, Massa, Federico, Cotta Ramusino, Matteo, Gandolfo, Federica, Nicolosi, Valentina, Orini, Stefania, Aarsland, Dag, Agosta, Federica, Babiloni, Claudio, Boada, Merce, Borroni, Barbara, Cappa, Stefano, Dubois, Bruno, Frederiksen, Kristian S., Froelich, Lutz, Garibotto, Valentina, Georges, Jean, Haliassos, Alexander, Hansson, Oskar, Jessen, Frank, Kamondi, Anita, Kessels, Roy P. C., Morbelli, Silvia, O'Brien, John T., Otto, Markus, Perret-Liaudet, Armand, Pizzini, Francesca B., Ritchie, Craig W., Scheltens, Philip, Vandenbulcke, Mathieu, Vanninen, Ritva, Verhey, Frans, Vernooij, Meike W., Yousry, Tarek, Van der Flier, Wiesje M., Nobili, Flavio, and Frisoni, Giovanni B.
- Abstract
Introduction Etiological diagnosis of neurocognitive disorders of middle-old age relies on biomarkers, although evidence for their rational use is incomplete. A European task force is defining a diagnostic workflow where expert experience fills evidence gaps for biomarker validity and prioritization. We report methodology and preliminary results. Methods Using a Delphi consensus method supported by a systematic literature review, 22 delegates from 11 relevant scientific societies defined workflow assumptions. Results We extracted diagnostic accuracy figures from literature on the use of biomarkers in the diagnosis of main forms of neurocognitive disorders. Supported by this evidence, panelists defined clinical setting (specialist outpatient service), application stage (MCI-mild dementia), and detailed pre-assessment screening (clinical-neuropsychological evaluations, brain imaging, and blood tests). Discussion The Delphi consensus on these assumptions set the stage for the development of the first pan-European workflow for biomarkers' use in the etiological diagnosis of middle-old age neurocognitive disorders at MCI-mild dementia stages. Highlights Rational use of biomarkers in neurocognitive disorders lacks consensus in Europe. A consensus of experts will define a workflow for the rational use of biomarkers. The diagnostic workflow will be patient-centered and based on clinical presentation. The workflow will be updated as new evidence accrues.
- Published
- 2023
15. Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study
- Author
-
Bruun, Marie, Frederiksen, Kristian S., Rhodius-Meester, Hanneke F. M., Baroni, Marta, Gjerum, Le, Koikkalainen, Juha, Urhemaa, Timo, Tolonen, Antti, van Gils, Mark, Rueckert, Daniel, Dyremose, Nadia, Andersen, Birgitte B., Lemstra, Afina W., Hallikainen, Merja, Kurl, Sudhir, Herukka, Sanna-Kaisa, Remes, Anne M., Waldemar, Gunhild, Soininen, Hilkka, Mecocci, Patrizia, van der Flier, Wiesje M., Lötjönen, Jyrki, and Hasselbalch, Steen G.
- Published
- 2019
- Full Text
- View/download PDF
16. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity
- Author
-
Albert, Marilyn S., Bennet, David, Camicioli, Richard, Collins, D. Louis, Dubois, Bruno, Hampel, Harald, denHeijer, Tom, Hock, Christofer, Jagust, William, Launer, Leonore, Maller, Jerome J., Mueller, Susan, Sachdev, Perminder, Simmons, Andy, Thompson, Paul M., Visser, Peter-Jelle, Wahlund, Lars-Olof, Weiner, Michael W., Winblad, Bengt, Frisoni, Giovanni B., Jack, Clifford R., Jr., Bocchetta, Martina, Bauer, Corinna, Frederiksen, Kristian S., Liu, Yawu, Preboske, Gregory, Swihart, Tim, Blair, Melanie, Cavedo, Enrica, Grothe, Michel J., Lanfredi, Mariangela, Martinez, Oliver, Nishikawa, Masami, Portegies, Marileen, Stoub, Travis, Ward, Chadwich, Apostolova, Liana G., Ganzola, Rossana, Wolf, Dominik, Barkhof, Frederik, Bartzokis, George, DeCarli, Charles, Csernansky, John G., deToledo-Morrell, Leyla, Geerlings, Mirjam I., Kaye, Jeffrey, Killiany, Ronald J., Lehéricy, Stephane, Matsuda, Hiroshi, O'Brien, John, Silbert, Lisa C., Scheltens, Philip, Soininen, Hilkka, Teipel, Stefan, Waldemar, Gunhild, Fellgiebel, Andreas, Barnes, Josephine, Firbank, Michael, Gerritsen, Lotte, Henneman, Wouter, Malykhin, Nikolai, Pruessner, Jens C., Wang, Lei, Watson, Craig, Wolf, Henrike, deLeon, Mony, Pantel, Johannes, Ferrari, Clarissa, Bosco, Paolo, Pasqualetti, Patrizio, Duchesne, Simon, Duvernoy, Henri, and Boccardi, Marina
- Published
- 2015
- Full Text
- View/download PDF
17. Prioritization process for European Academy of Neurology clinical practice guidelines
- Author
-
Aleksovska, Katina, primary, Bassetti, Claudio L. A., additional, Berger, Thomas, additional, Carvalho, Vanessa, additional, Costa, Joao, additional, Deuschl, Günther, additional, Frederiksen, Kristian S., additional, Jaarsma, Joke, additional, Kobulashvili, Teia, additional, Leone, Maurizio, additional, Pavlakova, Lucia, additional, Romoli, Michele, additional, and Vignatelli, Luca, additional
- Published
- 2022
- Full Text
- View/download PDF
18. European consensus for the diagnosis of MCI and mild dementia: Preparatory phase
- Author
-
Festari, Cristina, primary, Massa, Federico, additional, Cotta Ramusino, Matteo, additional, Gandolfo, Federica, additional, Nicolosi, Valentina, additional, Orini, Stefania, additional, Aarsland, Dag, additional, Agosta, Federica, additional, Babiloni, Claudio, additional, Boada, Mercè, additional, Borroni, Barbara, additional, Cappa, Stefano, additional, Dubois, Bruno, additional, Frederiksen, Kristian S., additional, Froelich, Lutz, additional, Garibotto, Valentina, additional, Georges, Jean, additional, Haliassos, Alexander, additional, Hansson, Oskar, additional, Jessen, Frank, additional, Kamondi, Anita, additional, Kessels, Roy P. C., additional, Morbelli, Silvia, additional, O'Brien, John T., additional, Otto, Markus, additional, Perret‐Liaudet, Armand, additional, Pizzini, Francesca B., additional, Ritchie, Craig W., additional, Scheltens, Philip, additional, Vandenbulcke, Mathieu, additional, Vanninen, Ritva, additional, Verhey, Frans, additional, Vernooij, Meike W., additional, Yousry, Tarek, additional, Van Der Flier, Wiesje M., additional, Nobili, Flavio, additional, and Frisoni, Giovanni B., additional
- Published
- 2022
- Full Text
- View/download PDF
19. Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics
- Author
-
Thorlacius-Ussing, Gorm, Bruun, Marie, Gjerum, Le, Frederiksen, Kristian S., Rhodius-Meester, Hanneke F. M., van der Flier, Wiesje M., Waldemar, Gunhild, Hasselbalch, Steen G., Nobili, Flavio, Internal medicine, Neurology, Amsterdam Neuroscience - Neurodegeneration, APH - Personalized Medicine, and APH - Methodology
- Subjects
Male ,medicine.medical_specialty ,Consensus ,Visual analogue scale ,Lewy body disease ,frontotemporal dementia ,Diagnosis, Differential ,Multidisciplinary approach ,Physicians ,differential diagnosis ,medicine ,Dementia ,Humans ,Cognitive Dysfunction ,Prospective Studies ,Cognitive decline ,Medical diagnosis ,Prospective cohort study ,Vascular dementia ,Intensive care medicine ,Aged ,clinical decision-making ,Patient Care Team ,business.industry ,General Neuroscience ,vascular dementia ,General Medicine ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,Clinical Psychology ,Female ,Geriatrics and Gerontology ,Differential diagnosis ,Alzheimer disease ,business ,dementia ,Research Article - Abstract
Background: Evidence-based recommendations on the optimal evaluation approach for dementia diagnostics are limited. This impedes a harmonized workup across clinics and nations. Objective: To evaluate the diagnostic performance of a multidisciplinary consensus conference compared to a single clinician approach. Methods: In this prospective study, we enrolled 457 patients with suspected cognitive decline, from two European memory clinics. A diagnostic evaluation was performed at baseline independently in two ways: 1) by a single clinician and 2) at a multidisciplinary consensus conference. A syndrome diagnosis and an etiological diagnosis was made. The confidence in the diagnosis was recorded using a visual analogue scale. An expert panel re-evaluation diagnosis served as reference for the baseline syndrome diagnosis and a 12-24-month follow-up diagnosis for the etiological diagnosis. Results: 439 patients completed the study. We observed 12.5%discrepancy (k = 0.81) comparing the baseline syndrome diagnoses of the single clinician to the consensus conference, and 22.3%discrepancy (k = 0.68) for the baseline etiological diagnosis. The accuracy of the baseline etiological diagnosis was significantly higher at the consensus conference and was driven mainly by increased accuracy in the MCI group. Confidence in the etiological diagnosis at baseline was significantly higher at the consensus conference (p
- Published
- 2021
- Full Text
- View/download PDF
20. European consensus for the diagnosis of MCI and mild dementia: Preparatory phase.
- Author
-
Festari, Cristina, Massa, Federico, Cotta Ramusino, Matteo, Gandolfo, Federica, Nicolosi, Valentina, Orini, Stefania, Aarsland, Dag, Agosta, Federica, Babiloni, Claudio, Boada, Mercè, Borroni, Barbara, Cappa, Stefano, Dubois, Bruno, Frederiksen, Kristian S., Froelich, Lutz, Garibotto, Valentina, Georges, Jean, Haliassos, Alexander, Hansson, Oskar, and Jessen, Frank
- Abstract
Introduction: Etiological diagnosis of neurocognitive disorders of middle‐old age relies on biomarkers, although evidence for their rational use is incomplete. A European task force is defining a diagnostic workflow where expert experience fills evidence gaps for biomarker validity and prioritization. We report methodology and preliminary results. Methods: Using a Delphi consensus method supported by a systematic literature review, 22 delegates from 11 relevant scientific societies defined workflow assumptions. Results: We extracted diagnostic accuracy figures from literature on the use of biomarkers in the diagnosis of main forms of neurocognitive disorders. Supported by this evidence, panelists defined clinical setting (specialist outpatient service), application stage (MCI‐mild dementia), and detailed pre‐assessment screening (clinical‐neuropsychological evaluations, brain imaging, and blood tests). Discussion: The Delphi consensus on these assumptions set the stage for the development of the first pan‐European workflow for biomarkers' use in the etiological diagnosis of middle‐old age neurocognitive disorders at MCI‐mild dementia stages. Highlights: Rational use of biomarkers in neurocognitive disorders lacks consensus in Europe.A consensus of experts will define a workflow for the rational use of biomarkers.The diagnostic workflow will be patient‐centered and based on clinical presentation.The workflow will be updated as new evidence accrues. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Lack of association between prior depressive episodes and cerebral [11C]PiB binding
- Author
-
Madsen, Karine, Hasselbalch, Bo J., Frederiksen, Kristian S., Haahr, Mette E., Gade, Anders, Law, Ian, Price, Julie C., Knudsen, Gitte M., Kessing, Lars V., and Hasselbalch, Steen G.
- Published
- 2012
- Full Text
- View/download PDF
22. Callosal tissue loss parallels subtle decline in psychomotor speed. A longitudinal quantitative MRI study. The LADIS Study
- Author
-
Jokinen, Hanna, Frederiksen, Kristian S., Garde, Ellen, Skimminge, Arnold, Siebner, Hartwig, Waldemar, Gunhild, Ylikoski, Raija, Madureira, Sofia, Verdelho, Ana, van Straaten, Elizabeth C.W., Barkhof, Frederik, Fazekas, Franz, Schmidt, Reinhold, Pantoni, Leonardo, Inzitari, Domenico, and Erkinjuntti, Timo
- Published
- 2012
- Full Text
- View/download PDF
23. Prioritization process for European Academy of Neurology clinical practice guidelines.
- Author
-
Aleksovska, Katina, Bassetti, Claudio L. A., Berger, Thomas, Carvalho, Vanessa, Costa, Joao, Deuschl, Günther, Frederiksen, Kristian S., Jaarsma, Joke, Kobulashvili, Teia, Leone, Maurizio, Pavlakova, Lucia, Romoli, Michele, and Vignatelli, Luca
- Subjects
DELPHI method ,COMMUNITIES ,NEUROLOGY - Abstract
Background and purpose: The development of high‐quality clinical practice guidelines (CPGs) takes substantial time, effort, and resources. During the past years, the European Academy of Neurology (EAN) guideline production was significantly increased, so the need to develop clear, transparent, and methodologically solid criteria for prioritizing guideline topics became apparent. With this paper, we aim to define a set of criteria to be applied for prioritizing topics for future EAN guidelines, as well as the procedure for their implementation. Methods: After review of the literature, we identified a recent systematic review that reported on the main prioritization criteria used by health organizations. Based on these, we developed a list of 20 preliminary criteria, which were voted on through a Delphi consensus procedure, including 160 stakeholders. Finally, we established a working procedure on how to submit and select new guideline topic proposals within the EAN. This procedure was reviewed by the EAN Scientific Committee and the Board. Results: The first round, 61.3% of the participants voted, and 86% of them participated in the second round. Seven criteria were approved with this procedure. After the selection of the criteria, a prioritization procedure was launched, and the first 30 topics are reported in this paper. This bottom‐up process that involved the whole EAN community was followed by a top‐down process, using additional criteria for further selection by the EAN board members. Conclusions: We describe the development of prioritization criteria to be applied in the process of topic selection for future EAN CPGs. We will perform regular reviews and adjustments of the process. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Chronic traumatic encephalopathy
- Author
-
Pourhadi, Nelsan, Ringkøbing, Signe P, Waldemar, Gunhild, and Frederiksen, Kristian S
- Subjects
Humans ,Autopsy ,Chronic Traumatic Encephalopathy ,Sports - Abstract
Chronic traumatic encephalopathy (CTE) is associated with a history of repetitive head impacts, such as those sustained through contact sports. Post-mortem assessment has revealed specific neuropathological characteristics related to the condition. The symptoms of CTE typically present several years after exposure and can include mood/behavioural changes, cognitive dysfunction and motor symptoms. The course of CTE can potentially be progressive and debilitating. In this review, we argue, that there is a need for validated neuropathological and clinical criteria in order to detect CTE ante-mortem in the population.
- Published
- 2021
25. Kronisk traumatisk encefalopati
- Author
-
Pourhadi, Nelsan, Ringkøbing, Signe P, Waldemar, Gunhild, Frederiksen, Kristian S, Pourhadi, Nelsan, Ringkøbing, Signe P, Waldemar, Gunhild, and Frederiksen, Kristian S
- Abstract
Chronic traumatic encephalopathy (CTE) is associated with a history of repetitive head impacts, such as those sustained through contact sports. Post-mortem assessment has revealed specific neuropathological characteristics related to the condition. The symptoms of CTE typically present several years after exposure and can include mood/behavioural changes, cognitive dysfunction and motor symptoms. The course of CTE can potentially be progressive and debilitating. In this review, we argue, that there is a need for validated neuropathological and clinical criteria in order to detect CTE ante-mortem in the population.
- Published
- 2021
26. Pharmacological Medical Treatment of Epilepsy in Patients with Dementia:A Systematic Review
- Author
-
Musaeus, Christian S., Nilsson, Christer, Cooper, Chris, Kramberger, Milica G., Verdelho, Ana, Stefanova, Elka, Religa, Dorota, Waldemar, Gunhild, Frederiksen, Kristian S., Musaeus, Christian S., Nilsson, Christer, Cooper, Chris, Kramberger, Milica G., Verdelho, Ana, Stefanova, Elka, Religa, Dorota, Waldemar, Gunhild, and Frederiksen, Kristian S.
- Abstract
Background: Patients with dementia have an increased risk of developing epilepsy, es-pecially in patients with vascular dementia and Alzheimer’s disease. In selecting the optimal an-ti-epileptic drug (AED), the possible side effects such as drowsiness and worsening of cognitive function should be taken into consideration, together with co-morbidities and type of epilepsy. Objective: The current systematic review investigates the efficacy, tolerability, and changes in cognitive function after administration of AED in patients with dementia and epilepsy. Methods: We searched six databases, including MEDLINE and CENTRAL, checked reference lists, contacted experts, and searched Google Scholar to identify studies reporting randomized trials. Studies identified were independently screened, data extracted, and quality appraised by two researchers. A narrative synthesis was used to report findings. Results: We included one study with 95 patients with Alzheimer’s disease randomized to either lev-etiracetam, lamotrigine, or phenobarbital. No significant differences were found for efficacy, but patients receiving levetiracetam showed an improvement in mini-mental state examination scores and had fewer adverse events. Conclusion: High-quality evidence in the form of randomized controlled trials to guide clinicians in choosing an AED in patients with dementia and concomitant epilepsy remains scarce. However, levetiracetam has previously been shown to possibly improve cognition in patients with both mild cognitive impairment and Alzheimer’s disease, is better tolerated in the elderly population, and has no clinically relevant interaction with either cholinesterase inhibitors or NMDA receptor antagon-ists. Registration No: The protocol was registered in the PROSPERO database (ID: CRD42020176252).
- Published
- 2021
27. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment:A European Alzheimer's disease consortium survey
- Author
-
Frederiksen, Kristian S., Nielsen, Thomas R., Appollonio, Ildebrando, Andersen, Birgitte Bo, Riverol, Mario, Boada, Mercè, Ceccaldi, Mathieu, Dubois, Bruno, Engelborghs, Sebastiaan, Frölich, Lutz, Hausner, Lucrezia, Gabelle, Audrey, Gabryelewicz, Tomasz, Grimmer, Timo, Hanseeuw, Bernard, Hort, Jakub, Hugon, Jacques, Jelic, Vesna, Koivisto, Anne, Kramberger, Milica G., Lebouvier, Thibaud, Lleó, Alberto, de Mendonça, Alexandre, Nobili, Flavio, Ousset, Pierre Jean, Perneczky, Robert, Olde Rikkert, Marcel, Robinson, David, Rouaud, Olivier, Sánchez, Elisabet, Santana, Isabel, Scarmeas, Nikolaos, Sheardova, Katerina, Sloan, Stephanie, Spiru, Luiza, Stefanova, Elka, Traykov, Latchezar, Yener, Görsev, Waldemar, Gunhild, Frederiksen, Kristian S., Nielsen, Thomas R., Appollonio, Ildebrando, Andersen, Birgitte Bo, Riverol, Mario, Boada, Mercè, Ceccaldi, Mathieu, Dubois, Bruno, Engelborghs, Sebastiaan, Frölich, Lutz, Hausner, Lucrezia, Gabelle, Audrey, Gabryelewicz, Tomasz, Grimmer, Timo, Hanseeuw, Bernard, Hort, Jakub, Hugon, Jacques, Jelic, Vesna, Koivisto, Anne, Kramberger, Milica G., Lebouvier, Thibaud, Lleó, Alberto, de Mendonça, Alexandre, Nobili, Flavio, Ousset, Pierre Jean, Perneczky, Robert, Olde Rikkert, Marcel, Robinson, David, Rouaud, Olivier, Sánchez, Elisabet, Santana, Isabel, Scarmeas, Nikolaos, Sheardova, Katerina, Sloan, Stephanie, Spiru, Luiza, Stefanova, Elka, Traykov, Latchezar, Yener, Görsev, and Waldemar, Gunhild
- Abstract
Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI. Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI. Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI. Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.
- Published
- 2021
28. Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort
- Author
-
Muurling, Marijn, Rhodius-Meester, Hanneke F.M., Pärkkä, Juha, Van Gils, Mark, Frederiksen, Kristian S., Bruun, Marie, Hasselbalch, Steen G., Soininen, Hilkka, Herukka, Sanna Kaisa, Hallikainen, Merja, Teunissen, Charlotte E., Visser, Pieter Jelle, Scheltens, Philip, Van Der Flier, Wiesje M., Mattila, Jussi, Lötjönen, Jyrki, De Boer, Casper, Muurling, Marijn, Rhodius-Meester, Hanneke F.M., Pärkkä, Juha, Van Gils, Mark, Frederiksen, Kristian S., Bruun, Marie, Hasselbalch, Steen G., Soininen, Hilkka, Herukka, Sanna Kaisa, Hallikainen, Merja, Teunissen, Charlotte E., Visser, Pieter Jelle, Scheltens, Philip, Van Der Flier, Wiesje M., Mattila, Jussi, Lötjönen, Jyrki, and De Boer, Casper
- Abstract
Background: Gait analysis with accelerometers is a relatively inexpensive and easy to use method to potentially support clinical diagnoses of Alzheimer's disease and other dementias. It is not clear, however, which gait features are most informative and how these measures relate to Alzheimer's disease pathology. Objective: In this study, we tested if calculated features of gait 1) differ between cognitively normal subjects (CN), mild cognitive impairment (MCI) patients, and dementia patients, 2) are correlated with cerebrospinal fluid (CSF) biomarkers related to Alzheimer's disease, and 3) predict cognitive decline. Methods: Gait was measured using tri-axial accelerometers attached to the fifth lumbar vertebra (L5) in 58 CN, 58 MCI, and 26 dementia participants, while performing a walk and dual task. Ten gait features were calculated from the vertical L5 accelerations, following principal component analysis clustered in four domains, namely pace, rhythm, time variability, and length variability. Cognitive decline over time was measured using MMSE, and CSF biomarkers were available in a sub-group. Results: Linear mixed models showed that dementia patients had lower pace scores than MCI patients and CN subjects (p < 0.05). In addition, we found associations between the rhythm domain and CSF-tau, especially in the dual task. Gait was not associated with CSF Aβ42 levels and cognitive decline over time as measured with the MMSE. Conclusion: These findings suggest that gait-particularly measures related to pace and rhythm-are altered in dementia and have a direct link with measures of neurodegeneration.
- Published
- 2020
29. Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy
- Author
-
Rhodius-Meester, Hanneke F M, van Maurik, Ingrid S, Koikkalainen, Juha, Tolonen, Antti, Frederiksen, Kristian S, Hasselbalch, Steen G, Soininen, Hilkka, Herukka, Sanna-Kaisa, Remes, Anne M, Teunissen, Charlotte E, Barkhof, Frederik, Pijnenburg, Yolande A L, Scheltens, Philip, Lötjönen, Jyrki, van der Flier, Wiesje M, Rhodius-Meester, Hanneke F M, van Maurik, Ingrid S, Koikkalainen, Juha, Tolonen, Antti, Frederiksen, Kristian S, Hasselbalch, Steen G, Soininen, Hilkka, Herukka, Sanna-Kaisa, Remes, Anne M, Teunissen, Charlotte E, Barkhof, Frederik, Pijnenburg, Yolande A L, Scheltens, Philip, Lötjönen, Jyrki, and van der Flier, Wiesje M
- Abstract
INTRODUCTION: An accurate and timely diagnosis for Alzheimer's disease (AD) is important, both for care and research. The current diagnostic criteria allow the use of CSF biomarkers to provide pathophysiological support for the diagnosis of AD. How these criteria should be operationalized by clinicians is unclear. Tools that guide in selecting patients in which CSF biomarkers have clinical utility are needed. We evaluated computerized decision support to select patients for CSF biomarker determination.METHODS: We included 535 subjects (139 controls, 286 Alzheimer's disease dementia, 82 frontotemporal dementia and 28 vascular dementia) from three clinical cohorts. Positive (AD like) and negative (normal) CSF biomarker profiles were simulated to estimate whether knowledge of CSF biomarkers would impact (confidence in) diagnosis. We applied these simulated CSF values and combined them with demographic, neuropsychology and MRI data to initiate CSF testing (computerized decision support approach). We compared proportion of CSF measurements and patients diagnosed with sufficient confidence (probability of correct class ≥0.80) based on an algorithm with scenarios without CSF (only neuropsychology, MRI and APOE), CSF according to the appropriate use criteria (AUC) and CSF for all patients.RESULTS: The computerized decision support approach recommended CSF testing in 140 (26%) patients, which yielded a diagnosis with sufficient confidence in 379 (71%) of all patients. This approach was more efficient than CSF in none (0% CSF, 308 (58%) diagnosed), CSF selected based on AUC (295 (55%) CSF, 350 (65%) diagnosed) or CSF in all (100% CSF, 348 (65%) diagnosed).CONCLUSIONS: We used a computerized decision support with simulated CSF results in controls and patients with different types of dementia. This approach can support clinicians in making a balanced decision in ordering additional biomarker testing. Computer-supported prediction restricts CSF testing to
- Published
- 2020
30. The role of physical and cognitive function in performance of activities of daily living in patients with mild-to-moderate Alzheimer’s disease – a cross-sectional study
- Author
-
Clemmensen, Frederikke K., Hoffmann, Kristine, Siersma, Volkert, Sobol, Nanna, Beyer, Nina, Andersen, Birgitte B., Vogel, Asmus, Lolk, Annette, Gottrup, Hanne, Høgh, Peter, Waldemar, Gunhild, Hasselbalch, Steen G., Frederiksen, Kristian S., Clemmensen, Frederikke K., Hoffmann, Kristine, Siersma, Volkert, Sobol, Nanna, Beyer, Nina, Andersen, Birgitte B., Vogel, Asmus, Lolk, Annette, Gottrup, Hanne, Høgh, Peter, Waldemar, Gunhild, Hasselbalch, Steen G., and Frederiksen, Kristian S.
- Abstract
Background: Several factors may play a role in the ability of patients with Alzheimer’s disease to perform activities of daily living (ADL). The aim of this study was to examine the impact of different aspects of physical performance and cognitive functions on ADL in patients suffering from mild-to-moderate Alzheimer’s disease. Methods: We conducted secondary analyses on cross-sectional baseline data from the randomized controlled multicentre study “Preserving quality of life, physical health and functional ability in Alzheimer’s Disease: The effect of physical exercise” (ADEX). In total, 185 AD patients (76 women and 109 men), with a mean age on 70,4 years, were included. Data from physical performance tests (Astrand cycle test, Timed up & Go (TUG), Sit to Stand test (STS)) and cognitive tests (Mini Mental Status Examination (MMSE), Symbol Digit Modalities Test (SDMT), Stroop Color and Word test (Stroop)) were used. Their associations with ADL, measured on the ADCS-ADL scale was assessed in multivariable regression analyses. Results: SDMT and MMSE had significant, moderate correlations with total ADL (SDMT: r = 0.33, MMSE: r = 0.42) and instrumental ADL (SDMT: r = 0.31, MMSE: r = 0.42), but not with basic ADL. Adjusting for age and sex, the associations between SDMT and MMSE to total ADL and instrumental ADL persisted. No significant associations were found between Astrand, TUG, STS or Stroop and total ADL, basic ADL or instrumental ADL. Conclusion: Total ADL and instrumental ADL are associated with cognitive functions, including executive function. No significant association between examined physical performance parameters and ADL functions was observed, and consequently does not support an impact of physical function on ADL functions in patients with mild-to-moderate Alzheimer’s disease and relatively well-preserved physical function. Strategies aimed to improve cognition may be better suited to improve ADL function in patients with mild-to-moderate Alzhei
- Published
- 2020
31. Biomarker counseling, disclosure of diagnosis and follow‐up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey
- Author
-
Frederiksen, Kristian S., primary, Nielsen, Thomas R., additional, Appollonio, Ildebrando, additional, Andersen, Birgitte Bo, additional, Riverol, Mario, additional, Boada, Mercè, additional, Ceccaldi, Mathieu, additional, Dubois, Bruno, additional, Engelborghs, Sebastiaan, additional, Frölich, Lutz, additional, Hausner, Lucrezia, additional, Gabelle, Audrey, additional, Gabryelewicz, Tomasz, additional, Grimmer, Timo, additional, Hanseeuw, Bernard, additional, Hort, Jakub, additional, Hugon, Jacques, additional, Jelic, Vesna, additional, Koivisto, Anne, additional, Kramberger, Milica G., additional, Lebouvier, Thibaud, additional, Lleó, Alberto, additional, de Mendonça, Alexandre, additional, Nobili, Flavio, additional, Ousset, Pierre‐Jean, additional, Perneczky, Robert, additional, Olde Rikkert, Marcel, additional, Robinson, David, additional, Rouaud, Olivier, additional, Sánchez, Elisabet, additional, Santana, Isabel, additional, Scarmeas, Nikolaos, additional, Sheardova, Katerina, additional, Sloan, Stephanie, additional, Spiru, Luiza, additional, Stefanova, Elka, additional, Traykov, Latchezar, additional, Yener, Görsev, additional, and Waldemar, Gunhild, additional
- Published
- 2020
- Full Text
- View/download PDF
32. Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort
- Author
-
Muurling, Marijn, primary, Rhodius-Meester, Hanneke F.M., additional, Pärkkä, Juha, additional, van Gils, Mark, additional, Frederiksen, Kristian S., additional, Bruun, Marie, additional, Hasselbalch, Steen G., additional, Soininen, Hilkka, additional, Herukka, Sanna-Kaisa, additional, Hallikainen, Merja, additional, Teunissen, Charlotte E., additional, Visser, Pieter Jelle, additional, Scheltens, Philip, additional, van der Flier, Wiesje M., additional, Mattila, Jussi, additional, Lötjönen, Jyrki, additional, and de Boer, Casper, additional
- Published
- 2020
- Full Text
- View/download PDF
33. Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy
- Author
-
Rhodius-Meester, Hanneke F. M., primary, van Maurik, Ingrid S., additional, Koikkalainen, Juha, additional, Tolonen, Antti, additional, Frederiksen, Kristian S., additional, Hasselbalch, Steen G., additional, Soininen, Hilkka, additional, Herukka, Sanna-Kaisa, additional, Remes, Anne M., additional, Teunissen, Charlotte E., additional, Barkhof, Frederik, additional, Pijnenburg, Yolande A. L., additional, Scheltens, Philip, additional, Lötjönen, Jyrki, additional, and van der Flier, Wiesje M., additional
- Published
- 2020
- Full Text
- View/download PDF
34. Impact of a clinical decision support tool on prediction of progression in early-stage dementia:a prospective validation study
- Author
-
Bruun, Marie, Frederiksen, Kristian S, Rhodius-Meester, Hanneke F M, Baroni, Marta, Gjerum, Le, Koikkalainen, Juha, Urhemaa, Timo, Tolonen, Antti, van Gils, Mark, Rueckert, Daniel, Dyremose, Nadia, Andersen, Birgitte B, Lemstra, Afina W, Hallikainen, Merja, Kurl, Sudhir, Herukka, Sanna-Kaisa, Remes, Anne M, Waldemar, Gunhild, Soininen, Hilkka, Mecocci, Patrizia, van der Flier, Wiesje M, Lötjönen, Jyrki, Hasselbalch, Steen G, Bruun, Marie, Frederiksen, Kristian S, Rhodius-Meester, Hanneke F M, Baroni, Marta, Gjerum, Le, Koikkalainen, Juha, Urhemaa, Timo, Tolonen, Antti, van Gils, Mark, Rueckert, Daniel, Dyremose, Nadia, Andersen, Birgitte B, Lemstra, Afina W, Hallikainen, Merja, Kurl, Sudhir, Herukka, Sanna-Kaisa, Remes, Anne M, Waldemar, Gunhild, Soininen, Hilkka, Mecocci, Patrizia, van der Flier, Wiesje M, Lötjönen, Jyrki, and Hasselbalch, Steen G
- Abstract
BACKGROUND: In clinical practice, it is often difficult to predict which patients with cognitive complaints or impairment will progress or remain stable. We assessed the impact of using a clinical decision support system, the PredictND tool, to predict progression in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) in memory clinics.METHODS: In this prospective multicenter study, we included 429 patients with SCD (n = 230) and MCI (n = 199) (female 54%, age 67 ± 9, MMSE 28 ± 2) and followed them for at least 12 months. Based on all available patient baseline data (demographics, cognitive tests, cerebrospinal fluid biomarkers, and MRI), the PredictND tool provides a comprehensive overview of the data and a classification defining the likelihood of progression. At baseline, a clinician defined an expected follow-up diagnosis and estimated the level of confidence in their prediction using a visual analogue scale (VAS, 0-100%), first without and subsequently with the PredictND tool. As outcome measure, we defined clinical progression as progression from SCD to MCI or dementia, and from MCI to dementia. Correspondence between the expected and the actual clinical progression at follow-up defined the prognostic accuracy.RESULTS: After a mean follow-up time of 1.7 ± 0.4 years, 21 (9%) SCD and 63 (32%) MCI had progressed. When using the PredictND tool, the overall prognostic accuracy was unaffected (0.4%, 95%CI - 3.0%; + 3.9%; p = 0.79). However, restricting the analysis to patients with more certain classifications (n = 203), we found an increase of 3% in the accuracy (95%CI - 0.6%; + 6.5%; p = 0.11). Furthermore, for this subgroup, the tool alone showed a statistically significant increase in the prognostic accuracy compared to the evaluation without tool (6.4%, 95%CI 2.1%; 10.7%; p = 0.004). Specifically, the negative predictive value was high. Moreover, confidence in the prediction increased significantly (∆VAS = 4%, p
- Published
- 2019
35. Different combinations of diagnostic tests discriminate specific subtypes of dementia
- Author
-
Rhodius-Meester, Hanneke F.M., Bruun, Marie, Baroni, Marta, Gjerum, Le, Remes, Anne M., Urhemaa, Timo, Tolonen, Antti, Rueckert, Daniel, van Gils, Mark, Lemstra, Evelien, Barkhof, Frederik, Frederiksen, Kristian S., Waldemar, Gunhild, Scheltens, Philip, Soininen, Hilkka, Mecocci, Patrizia, Koikkalainen, Juha, Lötjönen, Jyrki, and van der Flier, Wiesje M.
- Published
- 2018
- Full Text
- View/download PDF
36. Detecting frontotemporal dementia using a novel MRI imaging biomarker:The anterior versus posterior index
- Author
-
Bruun, Marie, Koikkalainen, Juha, Rhodius-Meester, Hanneke F.M., Baroni, Marta, Gjerum, Le, van Gils, Mark, Soininen, Hilkka, Remes, Anne M., Waldemar, Gunhild, Mecocci, Patrizia, van der Flier, Wiesje M., Hasselbalch, Steen, Lötjönen, Jyrki, and Frederiksen, Kristian S.
- Published
- 2018
- Full Text
- View/download PDF
37. Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study
- Author
-
Bruun, Marie, primary, Frederiksen, Kristian S., additional, Rhodius-Meester, Hanneke F.M., additional, Baroni, Marta, additional, Gjerum, Le, additional, Koikkalainen, Juha, additional, Urhemaa, Timo, additional, Tolonen, Antti, additional, van Gils, Mark, additional, Tong, Tong, additional, Guerrero, Ricardo, additional, Rueckert, Daniel, additional, Dyremose, Nadia, additional, Andersen, Birgitte Bo, additional, Simonsen, Anja H., additional, Lemstra, Afina, additional, Hallikainen, Merja, additional, Kurl, Sudhir, additional, Herukka, Sanna-Kaisa, additional, Remes, Anne M., additional, Waldemar, Gunhild, additional, Soininen, Hilkka, additional, Mecocci, Patrizia, additional, van der Flier, Wiesje M., additional, Lötjönen, Jyrki, additional, and Hasselbalch, Steen G., additional
- Published
- 2019
- Full Text
- View/download PDF
38. The effect of physical exercise on cerebral blood flow in Alzheimer's disease
- Author
-
van der Kleij, Lisa A, Petersen, Esben T, Siebner, Hartwig R, Hendrikse, Jeroen, Frederiksen, Kristian S, Sobol, Nanna A, Hasselbalch, Steen G, Garde, Ellen, van der Kleij, Lisa A, Petersen, Esben T, Siebner, Hartwig R, Hendrikse, Jeroen, Frederiksen, Kristian S, Sobol, Nanna A, Hasselbalch, Steen G, and Garde, Ellen
- Published
- 2018
39. Prevalence of the apolipoprotein E epsilon 4 allele in amyloid beta positive subjects across the spectrum of Alzheimer's disease
- Author
-
Mattsson, Niklas, Mattsson, Niklas, Groot, Colin, Jansen, Willemijn J., Landau, Susan M., Villemagne, Victor L., Engelborghs, Sebastiaan, Mintun, Mark M., Lleo, Alberto, Molinuevo, Jose Luis, Jagust, William J., Frisoni, Giovanni B., Ivanoiu, Adrian, Chetelat, Gael, Oliveira, Catarina Resende, Rodrigue, Karen M., Kornhuber, Johannes, Wallin, Anders, Klimkowicz-Mrowiec, Aleksandra, Kandimalla, Ramesh, Popp, Julius, Aalten, Pauline P., Aarsland, Dag, Alcolea, Daniel, Almdahl, Ina S., Baldeiras, Ines, Buchem, Mark A., Cavedo, Enrica, Chen, Kewei, Cohen, Ann D., Foerster, Stefan, Fortea, Juan, Frederiksen, Kristian S., Freund-Levi, Yvonne, Gill, Kiran Dip, Gkatzima, Olymbia, Grimmer, Timo, Hampel, Harald, Herukka, Sanna-Kaisa, Johannsen, Peter, Laere, Koen, Leon, Mony J., Maier, Wolfgang, Marcusson, Jan, Meulenbroek, Olga, Mollergard, Hanne M., Morris, John C., Mroczko, Barbara, Nordlund, Arto, Prabhakar, Sudesh, Peters, Oliver, Rami, Lorena, Rodriguez-Rodriguez, Eloy, Roe, Catherine M., Ruther, Eckart, Santana, Isabel, Schroder, Johannes, Seo, Sang W., Soininen, Hilkka, Spiru, Luiza, Stomrud, Erik, Struyfs, Hanne, Teunissen, Charlotte E., Verhey, Frans R. J., Vos, Stephanie J. B., Doorn, Linda J. C. van Waalwijk, Waldemar, Gunhild, Wallin, Asa K., Wiltfang, Jens, Vandenberghe, Rik, Brooks, David J., Fladby, Tormod, Rowe, Christopher C., Drzezga, Alexander, Verbeek, Marcel M., Sarazin, Marie, Wolk, David A., Fleisher, Adam S., Klunk, William E., Na, Duk L., Sanchez-Juan, Pascual, Lee, Dong Young, Nordberg, Agneta, Tsolaki, Magda, Camus, Vincent, Rinne, Juha O., Fagan, Anne M., Zetterberg, Henrik, Blennow, Kaj, Rabinovici, Gil D., Hansson, Oskar, Berckel, Bart N. M., Flier, Wiesje M., Scheltens, Philip, Visser, Pieter Jelle, Ossenkoppele, Rik, Mattsson, Niklas, Mattsson, Niklas, Groot, Colin, Jansen, Willemijn J., Landau, Susan M., Villemagne, Victor L., Engelborghs, Sebastiaan, Mintun, Mark M., Lleo, Alberto, Molinuevo, Jose Luis, Jagust, William J., Frisoni, Giovanni B., Ivanoiu, Adrian, Chetelat, Gael, Oliveira, Catarina Resende, Rodrigue, Karen M., Kornhuber, Johannes, Wallin, Anders, Klimkowicz-Mrowiec, Aleksandra, Kandimalla, Ramesh, Popp, Julius, Aalten, Pauline P., Aarsland, Dag, Alcolea, Daniel, Almdahl, Ina S., Baldeiras, Ines, Buchem, Mark A., Cavedo, Enrica, Chen, Kewei, Cohen, Ann D., Foerster, Stefan, Fortea, Juan, Frederiksen, Kristian S., Freund-Levi, Yvonne, Gill, Kiran Dip, Gkatzima, Olymbia, Grimmer, Timo, Hampel, Harald, Herukka, Sanna-Kaisa, Johannsen, Peter, Laere, Koen, Leon, Mony J., Maier, Wolfgang, Marcusson, Jan, Meulenbroek, Olga, Mollergard, Hanne M., Morris, John C., Mroczko, Barbara, Nordlund, Arto, Prabhakar, Sudesh, Peters, Oliver, Rami, Lorena, Rodriguez-Rodriguez, Eloy, Roe, Catherine M., Ruther, Eckart, Santana, Isabel, Schroder, Johannes, Seo, Sang W., Soininen, Hilkka, Spiru, Luiza, Stomrud, Erik, Struyfs, Hanne, Teunissen, Charlotte E., Verhey, Frans R. J., Vos, Stephanie J. B., Doorn, Linda J. C. van Waalwijk, Waldemar, Gunhild, Wallin, Asa K., Wiltfang, Jens, Vandenberghe, Rik, Brooks, David J., Fladby, Tormod, Rowe, Christopher C., Drzezga, Alexander, Verbeek, Marcel M., Sarazin, Marie, Wolk, David A., Fleisher, Adam S., Klunk, William E., Na, Duk L., Sanchez-Juan, Pascual, Lee, Dong Young, Nordberg, Agneta, Tsolaki, Magda, Camus, Vincent, Rinne, Juha O., Fagan, Anne M., Zetterberg, Henrik, Blennow, Kaj, Rabinovici, Gil D., Hansson, Oskar, Berckel, Bart N. M., Flier, Wiesje M., Scheltens, Philip, Visser, Pieter Jelle, and Ossenkoppele, Rik
- Abstract
Introduction: Apolipoprotein E (APOE) epsilon 4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid beta(A beta) pathology. Methods: We included 3451 A beta+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE epsilon 4 prevalence in relation to age, sex, education, and geographical location. Results: The APOE epsilon 4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in A beta+ cognitively normal and A beta+ mild cognitive impairment (P <.05) but not in A beta+ AD dementia (P =.66). The prevalence was highest in Northern Europe but did not vary by sex or education. Discussion: The APOE E4 prevalence in AD was higher than that in previous studies, which did not require presence of A beta pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location. (C) 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
- Published
- 2018
40. The effect of physical exercise on cerebral blood flow in Alzheimer's disease
- Author
-
Researchgr. Neuroradiologie, Brain, MS Radiologie, Circulatory Health, van der Kleij, Lisa A, Petersen, Esben T, Siebner, Hartwig R, Hendrikse, Jeroen, Frederiksen, Kristian S, Sobol, Nanna A, Hasselbalch, Steen G, Garde, Ellen, Researchgr. Neuroradiologie, Brain, MS Radiologie, Circulatory Health, van der Kleij, Lisa A, Petersen, Esben T, Siebner, Hartwig R, Hendrikse, Jeroen, Frederiksen, Kristian S, Sobol, Nanna A, Hasselbalch, Steen G, and Garde, Ellen
- Published
- 2018
41. Biomarker counseling, disclosure of diagnosis and follow‐up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey.
- Author
-
Frederiksen, Kristian S., Nielsen, Thomas R., Appollonio, Ildebrando, Andersen, Birgitte Bo, Riverol, Mario, Boada, Mercè, Ceccaldi, Mathieu, Dubois, Bruno, Engelborghs, Sebastiaan, Frölich, Lutz, Hausner, Lucrezia, Gabelle, Audrey, Gabryelewicz, Tomasz, Grimmer, Timo, Hanseeuw, Bernard, Hort, Jakub, Hugon, Jacques, Jelic, Vesna, Koivisto, Anne, and Kramberger, Milica G.
- Subjects
- *
MILD cognitive impairment , *ALZHEIMER'S disease , *MEDICAL disclosure , *COUNSELING , *SUPPORT groups - Abstract
Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow‐up in European expert centers diagnosing patients with MCI. Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow‐up in MCI. Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre‐ and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI. Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. Prevalence of cerebral amyloid pathology in persons without dementia
- Author
-
Jansen, Willemijn J., Ossenkoppele, Rik, Knol, Dirk L., Tijms, Betty M., Scheltens, Philip, Verhey, Frans R. J., Visser, Pieter Jelle, Aalten, Pauline, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Roe, Catherine M., Rot, Uros, Rowe, Christopher C., Rüther, Eckart, Sabri, Osama, Sanchez-Juan, Páscual, Santana, Isabel, Sarazin, Marie, Schröder, Johannes, Schütte, Christin, Almdahl, Ina S., Seo, Sang W., Soetewey, Femke, Soininen, Hilkka, Spiru, Luiza, Struyfs, Hanne, Teunissen, Charlotte E., Tsolaki, Magda, Vandenberghe, Rik, Verbeek, Marcel M., Villemagne, Victor L., Arnold, Steven E., Vos, Stephanie J. B., van Waalwijk van Doorn, Linda J. C., Waldemar, Gunhild, Wallin, Anders, Wallin, Åsa K., Wiltfang, Jens, Wolk, David A., Zboch, Marzena, Zetterberg, Henrik, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart N. M., Bibeau, Kristen, Blennow, Kaj, Brooks, David J., van Buchem, Mark A., Camus, Vincent, Cavedo, Enrica, Chen, Kewei, Chetelat, Gael, Cohen, Ann D., Drzezga, Alexander, Engelborghs, Sebastiaan, Fagan, Anne M., Fladby, Tormod, Fleisher, Adam S., van der Flier, Wiesje M., Ford, Lisa, Förster, Stefan, Fortea, Juan, Foskett, Nadia, Frederiksen, Kristian S., Freund-Levi, Yvonne, Frisoni, Giovanni B., Froelich, Lutz, Gabryelewicz, Tomasz, Gill, Kiran Dip, Gkatzima, Olymbia, Gómez-Tortosa, Estrella, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Hildebrandt, Helmut, Ishihara, Lianna, Ivanoiu, Adrian, Jagust, William J., Johannsen, Peter, Kandimalla, Ramesh, Kapaki, Elisabeth, Klimkowicz-Mrowiec, Aleksandra, Klunk, William E., Köhler, Sebastian, Koglin, Norman, Kornhuber, Johannes, Kramberger, Milica G., Van Laere, Koen, Landau, Susan M., Lee, Dong Young, de Leon, Mony, Lisetti, Viviana, Lleó, Alberto, Madsen, Karine, Maier, Wolfgang, Marcusson, Jan, Mattsson, Niklas, De Mendonça, Alexandre, Meulenbroek, Olga, Meyer, Philipp T., Mintun, Mark A., Mok, Vincent, Molinuevo, José Luis, Møllergård, Hanne M., Morris, John C., Mroczko, Barbara, Van der Mussele, Stefan, Na, Duk L., Newberg, Andrew, Nordberg, Agneta, Nordlund, Arto, Novak, Gerald P., Paraskevas, George P., Parnetti, Lucilla, Perera, Gayan, Peters, Oliver, Popp, Julius, Prabhakar, Sudesh, Rabinovici, Gil D., Ramakers, Inez H. G. B., Rami, Lorena, Resende de Oliveira, Catarina, Rinne, Juha O., Rodrigue, Karen M., Rodríguez-Rodríguez, Eloy, and Repositório da Universidade de Lisboa
- Abstract
Copyright © 2015 American Medical Association. All rights reserved., Importance: Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies. Objective: To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI). Data sources: Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators. Study selection: Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity. Data extraction and synthesis: Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies. Main outcomes and measures: Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations. Results: The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality. Conclusions and relevance: Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia., The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement No. 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution. BIOMARKAPD is an EU Joint Programme–Neurodegenerative Disease Research (JPND) project. The project is supported through national funding organizations under the aegis of JPND (http://www.jpnd.eu). In the Netherlands, this is ZonMw. The DESCRIPA study was funded by the European Commission within the 5th framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission as part of the 6th framework programme (contract No. 37670). This research was performed within the framework of the Center for Translational Molecular Medicine (CTTM) (http://www.ctmm.nl), project LeARN (grant 02N-101). The AIBL study was funded in part by the study partners (Australian Commonwealth Scientific Industrial and Research Organization [CSIRO], Edith Cowan University [ECU], Mental Health Research Institute [MHRI], Alzheimer’s Australia [AA], National Ageing Research Institute [NARI], Austin Health, CogState, Hollywood Private Hospital, Sir Charles Gardner Hospital). The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as ongoing funding from the Science and Industry Endowment Fund (SIEF). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and the US Department of Defense ADNI (W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals; Eli Lilly; F. Hoffmann-La Roche and its affiliated company Genentech; GE Healthcare; Innogenetics; IXICO; Janssen Alzheimer Immunotherapy Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Medpace; Merck; Meso Scale Diagnostics; NeuroRx Research; Novartis Pharmaceuticals; Pfizer; Piramal Imaging; Servier; Synarc; and Takeda Pharmaceutical. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The Dementia Competence Network (DCN) has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420). Additional funding related to the randomized clinical trials came from Janssen-Cilag and Merz Pharmaceuticals. The latter funds were exclusively used for personnel, pharmaceuticals, blistering and shipment of medication, and monitoring and as capitation fees for recruiting centers. Funding source for the Chandigarh study is the Indian Council of Medical Research (ICMR), India. Funding for the St Louis contribution was provided by the National Institute on Aging (P50 AG005681, P01 AG003991, and P01 AG026276); Fred Simmons and Olga Mohan, and the Charles and Joanne Knight Alzheimer’s Research Initiative of the Washington University Knight Alzheimer’s Disease Research Center. The Tours study received financial support of the French Ministry of Health grant PHRC-N 2008 1004 and the EC-FP6-project DiMI, LSHB-CT-2005-512146. The Caen study was funded by Agence Nationale de la Recherche, Programme Hospitalier de Recherche Clinique, Région Basse Normandie, and Institut National de la Santé et de la Recherche Médicale (Inserm). The research leading to the Munich contribution to the Mattsson multicenter study has received funding from the program “Investissements d’avenir” (ANR-10-IAIHU-06). The study from Pittsburgh was supported by National Institutes of Health grants (P50 AG005133, R37 AG025516, P01 AG025204). The New York contributions to the Mattsson multicenter study were in part supported by P30 AG008051, R01 AG13616, R01 AG022374, and R01 AG12101. Data from Brescia in this article were collected by Translational Outpatient Memory Clinic (TOMC) working group at IRCCS Fatebenefratelli in Brescia, Italy. Contributors to the TOMC are G. Amicucci, S. Archetti, L. Benussi, G. Binetti, L. Bocchio-Chiavetto, C. Bonvicini, E. Canu, F. Caobelli, E. Cavedo, E. Chittò, M. Cotelli, M. Gennarelli, S. Galluzzi, C. Geroldi, R. Ghidoni, R. Giubbini, U. P. Guerra, G. Kuffenschin, G. Lussignoli, D. Moretti, B. Paghera, M. Parapini, C. Porteri, M. Romano, S. Rosini, I. Villa, R. Zanardini, and O. Zanetti. The JPND Project is supported in Italy by the Italian Ministry of Health. The assembling of the TU Munich data set was supported in part by the German research foundation (Deutsche Forschungsgemeinschaft) (HE 4560/1-2, DR 445/3-1 and DR 445/4-1 to A.D.), and by a KKF grant for clinical research of the Technische Universität München (to A.D. and T.G.). The Florbetaben phase 2 study from which data were derived for this multicenter evaluation was sponsored by Bayer Healthcare/Piramal Imaging (Berlin, Germany). This work was supported by the University of Antwerp Research Fund; the Alzheimer Research Foundation (SAO-FRA); the Research Foundation Flanders (FWO); the Agency for Innovation by Science and Technology (IWT); the Belgian Science Policy Office Interuniversity Attraction Poles (IAP) program; and the Flemish Government–initiated Methusalem excellence grant.
- Published
- 2015
43. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance : Evidence of validity
- Author
-
Frisoni, Giovanni B., Jack, Clifford R., Grothe, Michel J., Lanfredi, Mariangela, Martinez, Oliver, Nishikawa, Masami, Portegies, Marileen, Stoub, Travis, Ward, Chadwich, Apostolova, Liana G., Ganzola, Rossana, Wolf, Dominik, Bocchetta, Martina, Barkhof, Frederik, Bartzokis, George, DeCarli, Charles, Csernansky, John G., deToledo-Morrell, Leyla, Geerlings, Mirjam I., Kaye, Jeffrey, Killiany, Ronald J., Lehéricy, Stephane, Matsuda, Hiroshi, Bauer, Corinna, O'Brien, John, Silbert, Lisa C., Scheltens, Philip, Soininen, Hilkka, Teipel, Stefan, Waldemar, Gunhild, Fellgiebel, Andreas, Barnes, Josephine, Firbank, Michael, Gerritsen, Lotte, Frederiksen, Kristian S., Henneman, Wouter, Malykhin, Nikolai, Pruessner, Jens C., Wang, Lei, Watson, Craig, Wolf, Henrike, deLeon, Mony, Pantel, Johannes, Ferrari, Clarissa, Bosco, Paolo, Liu, Yawu, Pasqualetti, Patrizio, Duchesne, Simon, Duvernoy, Henri, Boccardi, Marina, Albert, Marilyn S., Bennet, David, Camicioli, Richard, Collins, D. Louis, Dubois, Bruno, Hampel, Harald, Preboske, Gregory, denHeijer, Tom, Hock, Christofer, Jagust, William, Launer, Leonore, Maller, Jerome J., Mueller, Susan, Sachdev, Perminder, Simmons, Andy, Thompson, Paul M., Visser, Peter-Jelle, Swihart, Tim, Wahlund, Lars-Olof, Weiner, Michael W., Winblad, Bengt, Blair, Melanie, Cavedo, Enrica, Radiology and nuclear medicine, Neurology, Psychiatry, NCA - Brain imaging technology, and NCA - neurodegeneration
- Subjects
Male ,Pathology ,Diagnostic criteria ,Epidemiology ,Image Processing ,genetics [Alzheimer Disease] ,Hippocampus ,Functional Laterality ,Imaging ,pathology [Alzheimer Disease] ,ddc:616.89 ,methods [Magnetic Resonance Imaging] ,Computer-Assisted ,Clinical trials ,ddc:150 ,methods [Image Processing, Computer-Assisted] ,Validation ,Image Processing, Computer-Assisted ,Segmentation ,HARP ,medicine.diagnostic_test ,Health Policy ,Organ Size ,Alzheimer's disease ,Middle Aged ,instrumentation [Magnetic Resonance Imaging] ,Manual segmentation ,Magnetic Resonance Imaging ,Psychiatry and Mental health ,Magnetic resonance ,Biomedical Imaging ,Female ,methods [Neuroimaging] ,methods [Imaging, Three-Dimensional] ,EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging Initiative ,medicine.medical_specialty ,Hippocampal volumetry ,Biomarkers ,Enrichment ,Harmonized protocol ,Standard operating procedures ,Concurrent validity ,Clinical Sciences ,Neuroimaging ,Article ,Cellular and Molecular Neuroscience ,Imaging, Three-Dimensional ,Developmental Neuroscience ,Clinical Research ,Alzheimer Disease ,medicine ,Humans ,ddc:610 ,Aged ,Protocol (science) ,Reproducibility ,Internet ,business.industry ,Neurosciences ,Reproducibility of Results ,Magnetic resonance imaging ,Brain Disorders ,pathology [Hippocampus] ,Geriatrics ,Three-Dimensional ,Neurology (clinical) ,Geriatrics and Gerontology ,Atrophy ,Nuclear medicine ,business - Abstract
BackgroundAn international Delphi panel has defined a harmonized protocol (HarP) for the manual segmentation of the hippocampus on MR. The aim of this study is to study the concurrent validity of the HarP toward local protocols, and its major sources of variance.MethodsFourteen tracers segmented 10 Alzheimer's Disease Neuroimaging Initiative (ADNI) cases scanned at 1.5 T and 3T following local protocols, qualified for segmentation based on the HarP through a standard web-platform and resegmented following the HarP. The five most accurate tracers followed the HarP to segment 15 ADNI cases acquired at three time points on both 1.5 T and 3T.ResultsThe agreement among tracers was relatively low with the local protocols (absolute left/right ICC 0.44/0.43) and much higher with the HarP (absolute left/right ICC 0.88/0.89). On the larger set of 15 cases, the HarP agreement within (left/right ICC range: 0.94/0.95 to 0.99/0.99) and among tracers (left/right ICC range: 0.89/0.90) was very high. The volume variance due to different tracers was 0.9% of the total, comparing favorably to variance due to scanner manufacturer (1.2), atrophy rates (3.5), hemispheric asymmetry (3.7), field strength (4.4), and significantly smaller than the variance due to atrophy (33.5%, P < .001), and physiological variability (49.2%, P < .001).ConclusionsThe HarP has high measurement stability compared with local segmentation protocols, and good reproducibility within and among human tracers. Hippocampi segmented with the HarP can be used as a reference for the qualification of human tracers and automated segmentation algorithms. published
- Published
- 2015
- Full Text
- View/download PDF
44. Moderate-to-high intensity physical exercise in patients with Alzheimer’s disease:a randomised controlled trial.
- Author
-
Hoffmann, Kristine, Sobol, Nanna A., Frederiksen, Kristian S., Beyer, Nina Ann-Marie, Vogel, Asmus Mejling, Vestergaard, Karsten, Brændgaard, Hans, Gottrup, Hanne, Lolk, Annette, Wermuth, Lene, Jacobsen, Søren, Laugesen, Lars P., Gergelyffy, Robert G., Høgh, Peter, Bjerregaard, Eva, Andersen, Birgitte Bo, Siersma, Volkert Dirk, Johannsen, Peter, Cotman, Carl W, Waldemar, Gunhild, Hasselbalch, Steen, Hoffmann, Kristine, Sobol, Nanna A., Frederiksen, Kristian S., Beyer, Nina Ann-Marie, Vogel, Asmus Mejling, Vestergaard, Karsten, Brændgaard, Hans, Gottrup, Hanne, Lolk, Annette, Wermuth, Lene, Jacobsen, Søren, Laugesen, Lars P., Gergelyffy, Robert G., Høgh, Peter, Bjerregaard, Eva, Andersen, Birgitte Bo, Siersma, Volkert Dirk, Johannsen, Peter, Cotman, Carl W, Waldemar, Gunhild, and Hasselbalch, Steen
- Abstract
Background: Studies of physical exercise in patients with Alzheimer’s disease (AD) are few and results have been inconsistent. Objective: To assess the effects of a moderate-to-high intensity aerobic exercise program in patients with mild AD. Methods: In a randomized controlled trial, we recruited 200 patients with mild AD to a supervised exercise group (60-min sessions three times a week for 16 weeks) or to a control group. Primary outcome was changed from baseline in cognitive performance estimated by Symbol Digit Modalities Test (SDMT) in the intention-to-treat (ITT) group. Secondary outcomes included changes in quality of life, ability to perform activities of daily living, and in neuropsychiatric and depressive symptoms. Results: The ITT analysis showed no significant differences between intervention and control groups in change from baseline of SDMT, other cognitive tests, quality of life, or activities of daily living. The change from baseline in Neuropsychiatric Inventory differed significantly in favor of the intervention group (mean: –3.5, 95% confidence interval (CI) –5.8 to –1.3, p = 0.002). In subjects who adhered to the protocol, we found a significant effect on change from baseline in SDMT as compared with the control group (mean: 4.2, 95% CI 0.5 to 7.9, p = 0.028), suggesting a dose-response relationship between exercise and cognition. Conclusions: This is the first randomized controlled trial with supervised moderate-to-high intensity exercise in patients with mild AD. Exercise reduced neuropsychiatric symptoms in patients with mild AD, with possible additional benefits of preserved cognition in a subgroup of patients exercising with high attendance and intensity.
- Published
- 2016
45. Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer’s Disease: A Randomized Controlled Trial
- Author
-
Hoffmann, Kristine, primary, Sobol, Nanna A., additional, Frederiksen, Kristian S., additional, Beyer, Nina, additional, Vogel, Asmus, additional, Vestergaard, Karsten, additional, Brændgaard, Hans, additional, Gottrup, Hanne, additional, Lolk, Annette, additional, Wermuth, Lene, additional, Jacobsen, Søren, additional, Laugesen, Lars P., additional, Gergelyffy, Robert G., additional, Høgh, Peter, additional, Bjerregaard, Eva, additional, Andersen, Birgitte B., additional, Siersma, Volkert, additional, Johannsen, Peter, additional, Cotman, Carl W., additional, Waldemar, Gunhild, additional, and Hasselbalch, Steen G., additional
- Published
- 2016
- Full Text
- View/download PDF
46. Biomarkører ved diagnostik af Alzheimers sygdom i tidlig fase
- Author
-
Frederiksen, Kristian S, Hasselbalch, Steen, Law, Ian, Højgaard, Liselotte, Waldemar, Gunhild, Frederiksen, Kristian S, Hasselbalch, Steen, Law, Ian, Højgaard, Liselotte, and Waldemar, Gunhild
- Abstract
Alzheimer's disease is responsible for 40-50% of dementia cases. Future treatment may include disease-modifying compounds unlikely to be efficient if administered late in the course, thus necessitating early diagnosis. Furthermore, revised diagnostic research criteria that include biomarkers of pathological accumulation of cortical beta-amyloid (decreased beta-amyloid in cerebrospinal fluid and amyloid imaging) and neurodegeneration (structural MRI and 18F-FDG-PET), have been published. Future research is needed to determine specific evidence-based application of these biomarkers in the clinic as well as discovery of novel biomarkers.
- Published
- 2015
47. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance:Evidence of validity
- Author
-
Frisoni, Giovanni B, Jack, Clifford R, Bocchetta, Martina, Bauer, Corinna, Frederiksen, Kristian S, Liu, Yawu, Preboske, Gregory, Swihart, Tim, Blair, Melanie, Cavedo, Enrica, Grothe, Michel J, Lanfredi, Mariangela, Martinez, Oliver, Nishikawa, Masami, Portegies, Marileen, Stoub, Travis, Ward, Chadwich, Apostolova, Liana G, Ganzola, Rossana, Wolf, Dominik, Barkhof, Frederik, Bartzokis, George, DeCarli, Charles, Csernansky, John G, deToledo-Morrell, Leyla, Geerlings, Mirjam I, Kaye, Jeffrey, Killiany, Ronald J, Lehéricy, Stephane, Matsuda, Hiroshi, O'Brien, John, Silbert, Lisa C, Scheltens, Philip, Soininen, Hilkka, Teipel, Stefan, Waldemar, Gunhild, Fellgiebel, Andreas, Barnes, Josephine, Firbank, Michael, Gerritsen, Lotte, Henneman, Wouter, Malykhin, Nikolai, Pruessner, Jens C, Wang, Lei, Watson, Craig, Wolf, Henrike, deLeon, Mony, Pantel, Johannes, Ferrari, Clarissa, Bosco, Paolo, Frisoni, Giovanni B, Jack, Clifford R, Bocchetta, Martina, Bauer, Corinna, Frederiksen, Kristian S, Liu, Yawu, Preboske, Gregory, Swihart, Tim, Blair, Melanie, Cavedo, Enrica, Grothe, Michel J, Lanfredi, Mariangela, Martinez, Oliver, Nishikawa, Masami, Portegies, Marileen, Stoub, Travis, Ward, Chadwich, Apostolova, Liana G, Ganzola, Rossana, Wolf, Dominik, Barkhof, Frederik, Bartzokis, George, DeCarli, Charles, Csernansky, John G, deToledo-Morrell, Leyla, Geerlings, Mirjam I, Kaye, Jeffrey, Killiany, Ronald J, Lehéricy, Stephane, Matsuda, Hiroshi, O'Brien, John, Silbert, Lisa C, Scheltens, Philip, Soininen, Hilkka, Teipel, Stefan, Waldemar, Gunhild, Fellgiebel, Andreas, Barnes, Josephine, Firbank, Michael, Gerritsen, Lotte, Henneman, Wouter, Malykhin, Nikolai, Pruessner, Jens C, Wang, Lei, Watson, Craig, Wolf, Henrike, deLeon, Mony, Pantel, Johannes, Ferrari, Clarissa, and Bosco, Paolo
- Abstract
BACKGROUND: An international Delphi panel has defined a harmonized protocol (HarP) for the manual segmentation of the hippocampus on MR. The aim of this study is to study the concurrent validity of the HarP toward local protocols, and its major sources of variance.METHODS: Fourteen tracers segmented 10 Alzheimer's Disease Neuroimaging Initiative (ADNI) cases scanned at 1.5 T and 3T following local protocols, qualified for segmentation based on the HarP through a standard web-platform and resegmented following the HarP. The five most accurate tracers followed the HarP to segment 15 ADNI cases acquired at three time points on both 1.5 T and 3T.RESULTS: The agreement among tracers was relatively low with the local protocols (absolute left/right ICC 0.44/0.43) and much higher with the HarP (absolute left/right ICC 0.88/0.89). On the larger set of 15 cases, the HarP agreement within (left/right ICC range: 0.94/0.95 to 0.99/0.99) and among tracers (left/right ICC range: 0.89/0.90) was very high. The volume variance due to different tracers was 0.9% of the total, comparing favorably to variance due to scanner manufacturer (1.2), atrophy rates (3.5), hemispheric asymmetry (3.7), field strength (4.4), and significantly smaller than the variance due to atrophy (33.5%, P < .001), and physiological variability (49.2%, P < .001).CONCLUSIONS: The HarP has high measurement stability compared with local segmentation protocols, and good reproducibility within and among human tracers. Hippocampi segmented with the HarP can be used as a reference for the qualification of human tracers and automated segmentation algorithms.
- Published
- 2015
48. Physical Activity as a Moderator of Alzheimer Pathology: A Systematic Review of Observational Studies
- Author
-
Frederiksen, Kristian S., Gjerum, Le, Waldemar, Gunhild, and Hasselbalch, Steen Gregers
- Abstract
Introduction: Observational studies have found that physical activity is associated with a reduced risk of cognitive decline and dementia. Whether physical activity may also reduce the level of AD pathology, remains undetermined. Objective: To examine the relationship between physical activity and AD biomarkers (beta-amyloid1- 42, total tau and phosphorylated tau in CSF, amyloid PET, hippocampal atrophy on MRI and parietotemporal hypometabolism on brain 18F-FDG-PET). Methods: We carried out a systematic review of the observational studies of physical activity and AD biomarkers in healthy subjects, subjective cognitive complaints, mild cognitive impairment (MCI) and AD dementia. Results: We identified a total of 40 papers, which were eligible for inclusion. Thirty-four studies were conducted on healthy subjects, 3 on MCI and healthy subjects, 1 on MCI, and 2 on AD and healthy controls. Six studies reported on CSF biomarkers, 9 on amyloid PET, 29 on MRI and 4 on brain 18FFDG- PET. The majority of studies did not find a significant association between physical activity and AD biomarkers. Conclusion: The quality of included studies with only a few longitudinal studies, limits the conclusions which may be drawn from the present findings especially regarding the biomarkers other than hippocampal volume. However, the majority of the identified studies did not find a significant association.
- Published
- 2019
- Full Text
- View/download PDF
49. Moderate-to-high intensity aerobic exercise in patients with mild to moderate Alzheimer's disease:a pilot study
- Author
-
Frederiksen, Kristian S, Sobol, Nanna, Beyer, Nina, Hasselbalch, Steen, Waldemar, Gunhild, Frederiksen, Kristian S, Sobol, Nanna, Beyer, Nina, Hasselbalch, Steen, and Waldemar, Gunhild
- Abstract
OBJECTIVES: Physical exercise may modulate neuropathology and symptoms of Alzheimer's disease (AD). This pilot study assessed the feasibility of conducting a study of moderate-to-high intensity aerobic exercise in home-dwelling patients with mild AD.METHODS: An uncontrolled preintervention-postintervention test design with a single group receiving the same intervention. A total of eight patients with mild to moderate AD from the Copenhagen Memory clinic were included in the study. The intervention lasted for 14 weeks and consisted of supervised, 1-h sessions of aerobic exercise three times per week (50-60% of heart rate reserve for a two-week adaptation period and 70-80 % of heart rate reserve for the remaining 12 weeks) Feasibility was assessed based on acceptability, including attendance and drop-out, safety, and patients' and caregivers' attitudes towards the intervention as well as other relevant parameters.RESULTS: Attendance (mean, range: 90 %, 70-100 %) and retention (seven out of eight) rates were very high. No serious adverse events were observed. In general, patients and caregivers were positive towards the intervention.CONCLUSION: This study shows that it is feasible to conduct moderate-to-high intensity aerobic exercise in community-dwelling patients with mild AD. Our findings indicate that aspects such as a longer adaptation period, information about injury prevention, and need for involvement and support from caregivers should be addressed when planning an exercise intervention in an AD population.
- Published
- 2014
50. Moderate-to-high intensity aerobic exercise in patients with mild to moderate Alzheimer's disease: a pilot study
- Author
-
Frederiksen, Kristian S., primary, Sobol, Nanna, additional, Beyer, Nina, additional, Hasselbalch, Steen, additional, and Waldemar, Gunhild, additional
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.